AUS
NZ
UK
CA
USA
IND
.jpg)
Highlights
Acquisition transforms Roquefort into clinical-stage oncology firm
AO-252 licence targets aggressive cancers including brain metastases
Fundraise supports AO-252 development through upcoming trials
Roquefort Therapeutics acquires AO-252 cancer drug licence, strengthening its oncology pipeline and raising capital to accelerate clinical development and commercial positioning.
Transforming Roquefort into a Clinical-Stage Oncology Company
Roquefort Therapeutics (LSE:ROQ) is entering a new phase after acquiring an exclusive worldwide licence for the cancer drug AO-252, accompanied by a substantial fundraise to accelerate clinical development. This acquisition positions Roquefort as a clinical-stage oncology company with a strong focus on aggressive cancers.
The orally administered small molecule AO-252 targets TACC3, a protein often over-expressed in aggressive tumours. Its ability to cross the blood-brain barrier makes it suitable for tackling both primary tumours and brain metastases. This acquisition strengthens the company’s potential to impact multiple high-need cancer areas.
AO-252: Targeting High-Need Cancer Areas
AO-252 is currently undergoing phase I clinical trials in the United States for patients with advanced solid tumours. Early results have demonstrated encouraging tumour responses at low dose levels while maintaining a favourable safety profile. The trial has expanded to include ovarian and prostate cancers, highlighting the strategic focus on oncology areas with high unmet medical needs.
With global rights to AO-252, Roquefort can advance clinical development and explore strategic collaborations. This positions the company strongly in the precision oncology market, where therapies for targeted cancer treatment are highly valued.
Strategic Funding to Support Development
The fundraise provides capital to support ongoing clinical trials and development milestones for AO-252. This ensures the company can advance its clinical programme efficiently while preparing for upcoming data readouts that will inform potential commercial and strategic partnerships.
This development also coincides with a corporate restructuring to align Roquefort with its new focus on clinical-stage oncology. The company will undergo a rebranding and change its trading name to reflect the transformation of its business model.
Corporate Transformation and Market Positioning
Roquefort will rebrand as Coiled Therapeutics and transition to trading on AIM. The corporate changes include an overhaul of the board and leadership structure to strengthen the company’s clinical focus.
The move aligns with recent industry activity, demonstrating strong pharmaceutical interest in early-stage oncology assets. Comparisons can be drawn with major acquisitions of phase I/II cancer treatments, reflecting continued appetite for innovative therapies in targeted oncology.
Expanding the Oncology Pipeline
In addition to AO-252, Roquefort will evaluate its existing STAT-6 programme for potential clinical trials, creating a multi-asset oncology pipeline. The dual focus provides a stronger position in precision oncology and enhances opportunities for strategic partnerships.
The company’s presence in the LSE & FTSE stock market further supports visibility among investors, with inclusion in indices such as FTSE AIM 50 highlighting biotech growth potential. Updates on broader markets including FTSE 100 and FTSE 350 can provide context on investor trends and healthcare-focused equities.
Looking Ahead: Clinical Milestones and Market Potential
The AO-252 programme is expected to deliver key data readouts that will guide the next stages of development and inform potential partnerships. With a dual-asset pipeline, Roquefort aims to address unmet medical needs while establishing a solid position in precision oncology.
The company’s strategy aligns with global trends in targeted oncology treatments, highlighting the importance of early-stage clinical assets for pharmaceutical collaborations and industry growth.
